688289 Stock Overview
Engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Sansure Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.51 |
| 52 Week High | CN¥25.58 |
| 52 Week Low | CN¥16.08 |
| Beta | 0.69 |
| 1 Month Change | 2.32% |
| 3 Month Change | 20.44% |
| 1 Year Change | 20.44% |
| 3 Year Change | -43.26% |
| 5 Year Change | n/a |
| Change since IPO | -39.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688289 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | 0.9% | -0.5% | -0.5% |
| 1Y | 20.4% | -11.2% | 9.2% |
Return vs Industry: 688289 exceeded the CN Medical Equipment industry which returned -9.6% over the past year.
Return vs Market: 688289 exceeded the CN Market which returned 10.8% over the past year.
Price Volatility
| 688289 volatility | |
|---|---|
| 688289 Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688289 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688289's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 2,209 | Lizhong Dai | www.sansure.com.cn |
Sansure Biotech Inc. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments in China. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; and diagnostic kits for monkeypox, epstein-barr virus, and human cytomegalovirus DNA, as well as rapid antigen tests. The company provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents; sample storage reagents for SARS-CoV-2; extraction instruments and systems; and PCR instruments comprising real-time quantitative thermal cyclers, portable molecule workstations, and real-time PCR systems.
Sansure Biotech Inc. Fundamentals Summary
| 688289 fundamental statistics | |
|---|---|
| Market cap | CN¥12.89b |
| Earnings (TTM) | CN¥259.42m |
| Revenue (TTM) | CN¥1.41b |
49.7x
P/E Ratio9.2x
P/S RatioIs 688289 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688289 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.41b |
| Cost of Revenue | CN¥315.49m |
| Gross Profit | CN¥1.09b |
| Other Expenses | CN¥832.24m |
| Earnings | CN¥259.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 77.58% |
| Net Profit Margin | 18.44% |
| Debt/Equity Ratio | 5.6% |
How did 688289 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield100%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 08:55 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sansure Biotech Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaoling Wang | Chasing Securities |
| Shiyu Chen | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |